Business
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE)
About this update from Scisparc Ltd.
[{"type":"text","content":"Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\"Company\" or \"SciSparc\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”) at the Tel Aviv Sourasky Medical Center in Israel (“Sourasky”). The trial is based on the positive data results received from the single arm Yale School of Medicine study using SCI-110 for TS. \"The initiation of our Phase IIb Clinical Trial at Sourasky, the Israeli site, is a major milestone towards commercializing our proprietary SCI-110 for TS patients. TS in adults can be a debilitating disorder for which current treatments result in limited benefits. Encouraged by the results seen in the Phase IIa study at Yale School of Medicine, we look forward to continuing clinical research of the treatment regimen in this double-blind randomized trial,\" said SciSparc’s Chief Executive Officer, Oz Adler. \"This is an important area of growth for the Company, alongside the Company’s other proprietary platforms, including SCI-110 in patients with Alzheimer’s disease and agitation and SCI-210 for children suffering from autism spectrum disorder.\" The Phase IIb clinical trial will be conducted at three global leading centers of excellence: the Yale Child Study Center at the Yale School of Medicine in Connecticut, USA, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Israel. The Company has already secured the Institutional Review Board approvals from all three clinical sites, the Israeli Ministry of Health's approval for the clinical trial at Sourasky, and approval from the Federal Institute for Drugs and Medical Devices in Germany for conducting the trial at the Hannover Medical School. The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age) using a daily oral treatment. The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-1...